Australian-New Zealand Clinical Trial: A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Adaptive Dose-Selection Clinical Trial to Evaluate the Efficacy and Safety of ARG-007 in Patients with Acute Ischemic Stroke Due to Large Vessel Occlusion Undergoing Endovascular Thrombectomy

Australia, Nov. 10 -- The Australian New Zealand Clinical Trials Registry (ANZCTR) received information related to the study titled ‘A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Adaptive Dose-Selection Clinical Trial to Evaluate the Efficacy and Safety of ARG-007 in Patients with Acute Ischemic Stroke Due to Large Vessel Occlusion Undergoing Endovascular Thrombectomy’. The following are the other relevant details related to the trial:

Trial ID: 392811

Submit Date: 10/15/26 14:08

Study Type: Interventional

Intervention: Arm 1: ARG-007 (xaranetide) 1.5 mg/mL Arm 2: ARG-007 (xaranetide) 3.0 mg/mL Arm 3: placebo (vehicle) Investigational product administered as a single intravenous infusion over 10 minutes in hospi...